ribociclib
Showing 1 - 25 of 139
Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)
Not yet recruiting
- Metastatic Breast Cancer
- Fulvestrant plus AI plus ribociclib
- AI plus ribociclib
-
Seoul, Korea, Republic ofKorea university Guro hospital
Apr 16, 2023
Breast Cancer Trial in Ann Arbor (Ribociclib, Postoperative Radiation Therapy)
Not yet recruiting
- Breast Cancer
- Ribociclib
- Postoperative Radiation Therapy
-
Ann Arbor, MichiganUniversity of Michigan
Aug 10, 2023
Ribociclib in Combination With Hormonal Therapy in HR+/HER2-
Not yet recruiting
- Breast Cancer
- ribociclib
- (no location specified)
Oct 10, 2023
Early Breast Cancer Trial (Ribociclib, Letrozole, Ansastrozole)
Not yet recruiting
- Early Breast Cancer
- Ribociclib
- +4 more
- (no location specified)
Apr 12, 2023
Risarg® Combined With Endocrine Therapy or Chemotherapy in
Not yet recruiting
- HR+HER2- Advanced Breast Cancer
- Ribociclib
- Combination chemotherapy
- (no location specified)
Nov 20, 2023
Among HR+/HER2- Advanced or Metastatic Breast Cancer in France
Recruiting
- Breast Cancer
- ribociclib + ET
-
La Roche sur Yon Cedex, FranceNovartis Investigative Site
Jan 16, 2023
Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)
Recruiting
- Breast Cancer
- Ribociclib
- Endocrine therapy
-
Boston, Massachusetts
- +2 more
Jan 6, 2023
Ribociclib in Combination With Non-steroidal Aromatase
Completed
- Breast Cancer
- Ribociclib
-
Sao Paulo, SP, BrazilNovartis Investigative Site
Nov 7, 2022
Glioblastoma Multiforme, Glioma of Brain Trial in Chandler, Phoenix, Scottsdale (Ribociclib, Everolimus)
Completed
- Glioblastoma Multiforme
- Glioma of Brain
- Ribociclib
- Everolimus
-
Chandler, Arizona
- +2 more
Jan 11, 2023
A Deep Learning Method to Evaluate QT on Ribociclib
Not yet recruiting
- Breast Cancer
- Ribociclib
- Acquisition of a digitized ECG by four modalities within 20 minutes
-
Neuilly-sur-Seine, France
- +3 more
Nov 18, 2022
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in United
Recruiting
- Hormone-Resistant Prostate Cancer
- +3 more
- Enzalutamide
- Ribociclib
-
Ann Arbor, Michigan
- +3 more
Feb 2, 2023
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)
Completed
- Ovarian Cancer
- +2 more
- ribociclib
- +2 more
-
Ann Arbor, Michigan
- +7 more
Sep 1, 2022
Triple Negative Breast Cancer Trial in United States (ribociclib, Bicalutamide)
Recruiting
- Triple Negative Breast Cancer
- ribociclib
- Bicalutamide
-
Chicago, Illinois
- +5 more
Oct 31, 2022
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,
Not yet recruiting
- Locoregional Recurrence
- +2 more
- Ribociclib
- +4 more
- (no location specified)
Jul 18, 2022
Breast Cancer Trial in Prato (Ribociclib, Aromatase Inhibitors, non steroideal, LHRH agonist)
Recruiting
- Breast Cancer
- Ribociclib
- +2 more
-
Prato, Please Select:, ItalyHospital of Prato
Jul 27, 2022
HER2 Negative Breast Cancer Not Immediately Operated Trial (Ribociclib Oral Tablet)
Not yet recruiting
- HER2 Negative Breast Cancer Not Immediately Operated
- Ribociclib Oral Tablet
- (no location specified)
Dec 16, 2022
Head and Neck Squamous Cell Carcinoma Trial in Taipei (Ribociclib, Spartalizumab)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Ribociclib
- Spartalizumab
-
Taipei, TaiwanNational Taiwan University Hospital
Apr 19, 2022
Prostate Cancer Trial in United States (Docetaxel-PNP, Ribociclib, Prednisone)
Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma Trial in United States (ribociclib, Everolimus)
Completed
- Diffuse Intrinsic Pontine Glioma
- +6 more
- ribociclib
- Everolimus
-
Washington, District of Columbia
- +6 more
Jan 12, 2023
Lymphoma, Solid Tumor Trial in Buffalo (Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study)
Terminated
- Lymphoma
- Solid Neoplasm
- Gemcitabine Hydrochloride
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023